FILING ANALYSIS · TUESDAY, NOVEMBER 10
MAXCYTE, INC. MXCT — 8-K: Entry into a Material Definitive Agreement
negative
MaxCyte is acquiring Akron BioProducts for $105 million in cash, 20.6 million shares of common stock, and $20 million in deferred cash payments, which will lead to dilution for existing shareholders. The deal is subject to customary closing conditions and is expected to close before the end of 2026.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →